- Stocks
- Healthcare
- NASDAQ: INO

Price (delayed)

$12.01

Market cap

$2.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$1.93B

The equity has soared by 74% from the previous quarter

Inovio Pharmaceuticals's debt has decreased by 26% QoQ and by 20% YoY

INO's quick ratio has surged by 71% year-on-year but it is down by 15% since the previous quarter

INO's net income has dropped by 57% year-on-year but it is up by 19% since the previous quarter

The gross profit has dropped by 67% year-on-year and by 23% since the previous quarter

INO's revenue has dropped by 67% year-on-year and by 23% since the previous quarter

What are the main financial stats of INO

Market
Valuations
Earnings

Shares outstanding

169.41M

Market cap

$2.03B

Enterprise value

$1.93B

Price to earnings (P/E)

N/A

Price to book (P/B)

6.21

Price to sales (P/S)

941.14

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

914.89

Revenue

$2.11M

EBIT

-$169.52M

EBITDA

-$164.04M

Free cash flow

-$141.17M

Per share
Balance sheet
Liquidity

EPS

-$1.35

Free cash flow per share

-$0.85

Book value per share

$1.93

Revenue per share

$0.01

TBVPS

$2.56

Total assets

$437.81M

Total liabilities

$113.81M

Debt

$74.62M

Equity

$323.9M

Working capital

$335.8M

Debt to equity

0.23

Current ratio

9.14

Quick ratio

8.37

Net debt/EBITDA

0.63

Margins
Efficiency
Dividend

EBITDA margin

-7,774%

Gross margin

100%

Net margin

-8,517.7%

Operating margin

-5,931.6%

Return on assets

-52.7%

Return on equity

-103%

Return on invested capital

-70.4%

Return on capital employed

-42.7%

Return on sales

-8,033.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Inovio Pharmaceuticals stock price performed over time

Intraday

2.83%

1 week

-21.86%

1 month

33.44%

1 year

203.28%

YTD

35.71%

QTD

35.71%

How have Inovio Pharmaceuticals's revenue and profit performed over time

Revenue

$2.11M

Gross profit

$2.11M

Operating income

-$125.16M

Net income

-$179.73M

Gross margin

100%

Net margin

-8,517.7%

The gross profit has dropped by 67% year-on-year and by 23% since the previous quarter

INO's revenue has dropped by 67% year-on-year and by 23% since the previous quarter

INO's net income has dropped by 57% year-on-year but it is up by 19% since the previous quarter

The company's operating margin fell by 44% QoQ

What is Inovio Pharmaceuticals's growth rate over time

What is Inovio Pharmaceuticals stock price valuation

P/E

N/A

P/B

6.21

P/S

941.14

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

914.89

INO's EPS is up by 21% since the previous quarter but it is down by 14% year-on-year

The stock's price to book (P/B) is 81% less than its last 4 quarters average of 32.7 and 40% less than its 5-year quarterly average of 10.3

The equity has soared by 74% from the previous quarter

INO's revenue has dropped by 67% year-on-year and by 23% since the previous quarter

The P/S is 31% higher than the last 4 quarters average of 718.9

How efficient is Inovio Pharmaceuticals business performance

INO's ROE has soared by 53% from the previous quarter and by 43% YoY

INO's return on assets is up by 36% since the previous quarter and by 27% year-on-year

The company's return on invested capital rose by 27% QoQ but it fell by 6% YoY

INO's return on sales is down by 4.2% since the previous quarter

What is INO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INO.

How did Inovio Pharmaceuticals financials performed over time

INO's current ratio has soared by 81% YoY but it is down by 9% QoQ

INO's quick ratio has surged by 71% year-on-year but it is down by 15% since the previous quarter

Inovio Pharmaceuticals's debt is 77% lower than its equity

The debt to equity has plunged by 92% YoY and by 57% from the previous quarter

Inovio Pharmaceuticals's debt has decreased by 26% QoQ and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.